Literature DB >> 8501567

Long-term survival after Edmonston-Zagreb measles vaccination in Guinea-Bissau: increased female mortality rate.

P Aaby1, K Knudsen, H Whittle, I M Lisse, J Thaarup, A Poulsen, M Sodemann, M Jakobsen, L Brink, U Gansted.   

Abstract

In an urban area of Guinea-Bissau, 384 children were enrolled in a randomized trial comparing morbidity and mortality rates after receiving high-titer Edmonston-Zagreb (EZ) measles vaccine administered from 4 months of age, with a control group receiving inactivated poliomyelitis vaccine at 4 months of age and the standard Schwarz vaccine from 9 months of age. Children were followed to the age of at least 3 years. The mortality ratio of the EZ vaccinees compared with control subjects was 1.79 (range, 1.06 to 3.02; p = 0.027) if children were excluded at the time of migration; if deaths after migration were included, the mortality ratio was 1.53 (range, 0.94 to 2.49; p = 0.087). Girls in the EZ group had significantly higher mortality rates than girls in the control group (mortality ratio = 1.95; range, 1.07 to 3.56; p = 0.027); there was no difference for the boys (mortality ratio = 0.98; range, 0.41 to 2.30). Adjustment for background factors in a Cox regression model did not modify these estimates. Furthermore, female recipients of EZ vaccine had more days with diarrhea (relative risk = 1.35; range, 1.17 to 1.56; p = 0.00003) and were more likely than control subjects to visit a health center in the month after vaccination (relative risk = 1.86; range, 1.05 to 3.31; p = 0.027); those who consulted were more likely to die subsequently (mortality ratio = 2.31; range, 0.99 to 5.41; p = 0.054). These observations were unplanned and require confirmation in larger studies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8501567     DOI: 10.1016/s0022-3476(09)90015-4

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  31 in total

1.  Routine vaccination and child survival in Guinea-Bissau. Author's reply to commentary.

Authors:  P Aaby; H Jensen
Journal:  BMJ       Date:  2001-02-10

2.  Non-specific "non-effects" of vaccination.

Authors:  Paul E M Fine
Journal:  BMJ       Date:  2004-12-04

3.  Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries.

Authors:  P Aaby; B Samb; F Simondon; A M Seck; K Knudsen; H Whittle
Journal:  BMJ       Date:  1995-08-19

4.  Immunisation policies--successes, failures and the future.

Authors:  E Miller
Journal:  J Clin Pathol       Date:  1996-08       Impact factor: 3.411

5.  Nutritional status and delayed mortality following early exposure to measles.

Authors:  P Aaby; M Andersen; K Knudsen
Journal:  Epidemiol Infect       Date:  1996-12       Impact factor: 2.451

6.  Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies.

Authors:  B Schlereth; J K Rose; L Buonocore; V ter Meulen; S Niewiesk
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

7.  Sex-associated differences in the antibody-dependent cellular cytotoxicity antibody response to measles vaccines.

Authors:  S Atabani; G Landucci; M W Steward; H Whittle; J G Tilles; D N Forthal
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

8.  Safety and immunogenicity of early measles vaccination in children born to HIV-infected mothers in the United States: results of Pediatric AIDS Clinical Trials Group (PACTG) protocol 225.

Authors:  Sulachni Chandwani; Judy Beeler; Hong Li; Susette Audet; Betsy Smith; John Moye; David Nalin; Keith Krasinski
Journal:  J Infect Dis       Date:  2011-07       Impact factor: 5.226

9.  Functional and phenotypic changes in circulating lymphocytes from hospitalized zambian children with measles.

Authors:  Judith J Ryon; William J Moss; Mwaka Monze; Diane E Griffin
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

10.  Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial.

Authors:  Peter Aaby; Cesário L Martins; May-Lill Garly; Carlito Balé; Andreas Andersen; Amabelia Rodrigues; Henrik Ravn; Ida M Lisse; Christine S Benn; Hilton C Whittle
Journal:  BMJ       Date:  2010-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.